Adenomyosis: from scientific discoveries to the practical aspects of prescribing drug therapy
article
OA: closed
CC0
⤵ 7 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper reviews scientific discoveries and practical considerations for prescribing drug therapy in adenomyosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (7)
- Efficacy and safety endpoints of dienogest treatment of endometriosis: a systematic review 2025
- The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis 2024
- Blood oxytocin levels and the rs4686302 polymorphism of the oxytocin receptor gene in patients with adenomyosis 2023
- Endometrial receptivity in adenomyosis and the role of signaling pathways in the pathogenesis of the disease (literature review) 2022
- New possibilities of differential diagnosis of uterine fibroids and adenomyosis nodes based on a complex ultrasound assessment 2022
- Clinical significance of predictive and diagnostic indices of fetal pathology associated with placental insufficiency in women with endometriosis 2021
- Role of molecular signaling pathways in the pathogenesis of adenomyosis 2021
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK